ILR1 Antibody

What is IL-1R1 and why is it important in immunological research?

IL-1R1 (Interleukin-1 Receptor Type 1, also known as p80, IL-1R-alpha, or CD121a) is an 80 kDa transmembrane glycoprotein and a member of the interleukin-1 receptor family. It functions as a receptor for IL-1α, IL-1β, and interleukin-1 receptor antagonist (IL-1Ra) . When IL-1α and IL-1β interact with the extracellular domain of IL-1R1, they trigger recruitment of signaling molecules that activate multiple pathways involved in inflammation and immune responses. IL-1R1 plays crucial roles in both innate and adaptive immunity, particularly in T cell responses to viral antigens and the subsequent development of antibody responses . Understanding IL-1R1 signaling provides insights into fundamental immune mechanisms that are relevant to infectious diseases, autoimmunity, and vaccine development.

What are the key characteristics of IL-1R1 antibodies used in research?

IL-1R1 antibodies used in research are typically polyclonal or monoclonal antibodies designed to specifically recognize and bind to the IL-1R1 protein. Commercial antibodies such as the 27348-1-AP (a rabbit polyclonal IgG) have been validated for multiple applications including Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), and ELISA . These antibodies typically show reactivity with human and mouse samples, with observed molecular weights around 80 kDa and 60 kDa . The storage conditions generally require temperatures of -20°C in buffer solutions containing PBS with sodium azide and glycerol to maintain stability and activity . Different antibody clones may recognize distinct epitopes on IL-1R1, which affects their utility for specific applications and functional studies.

What applications are IL-1R1 antibodies most commonly used for?

IL-1R1 antibodies are utilized across multiple experimental applications including:

These applications enable researchers to detect, quantify, and visualize IL-1R1 expression across diverse experimental systems, from cell lines to tissue samples . Additionally, IL-1R1 antibodies are increasingly being incorporated into advanced techniques such as mass cytometry and single-cell RNA sequencing to characterize IL-1R1 expression at higher resolution .

How should experimental conditions be optimized for IL-1R1 antibody applications?

Optimizing experimental conditions for IL-1R1 antibody applications requires careful consideration of several parameters:

For Western Blot applications, IL-1R1 antibodies typically perform best at dilutions of 1:1000-1:4000 . Researchers should be aware that IL-1R1 may appear at both 80 kDa and 60 kDa, representing different forms of the receptor . Sample preparation methods should maintain protein integrity while ensuring efficient extraction.

For Immunohistochemistry applications, optimal results typically require antigen retrieval with TE buffer at pH 9.0, although citrate buffer at pH 6.0 can serve as an alternative . The recommended antibody dilutions range from 1:300-1:1200 . Positive controls should include tissues known to express IL-1R1, such as mouse spleen or human appendicitis tissue .

For all applications, it is imperative to titrate the antibody in each specific experimental system, as optimal concentrations may vary depending on the sample type and detection method . Including appropriate positive and negative controls is essential for validating specificity and optimizing signal-to-noise ratios.

What strategies can be employed to validate IL-1R1 antibody specificity?

Validating antibody specificity is crucial for generating reliable research data. For IL-1R1 antibodies, several complementary approaches can be employed:

• Molecular weight verification: Confirm that the antibody detects proteins at the expected molecular weights (approximately 80 kDa and 60 kDa for IL-1R1) .

• Genetic validation: Test the antibody in IL-1R1 knockout or knockdown samples to confirm loss of signal. This represents the gold standard for specificity validation.

• Peptide competition assays: Pre-incubate the antibody with the immunizing peptide to demonstrate that this blocks detection.

• Cross-reactivity assessment: Test the antibody against related proteins (other IL-1 receptor family members) to confirm specificity.

• Multiple antibody validation: Compare detection patterns using multiple antibodies targeting different epitopes of IL-1R1.

• Functional correlation: Confirm that detection of IL-1R1 correlates with expected biological outcomes, such as NF-κB activation in response to IL-1 stimulation .

These validation approaches provide complementary lines of evidence that collectively establish antibody specificity and reliability for research applications.

How do antibody-based assays for IL-1R1 compare with functional bioassays?

Antibody-based assays and functional bioassays provide complementary information about IL-1R1 biology, each with distinct advantages:

Antibody-based assays (such as ELISA, Western blot, and immunostaining) offer several advantages over functional bioassays:

• Higher specificity: Antibody-based assays can distinguish IL-1R1 from other related receptors, whereas bioassays may detect responses from multiple receptor types .

• Greater sensitivity in complex samples: Bioassays often exhibit reduced sensitivity in complex biological fluids due to non-specific protein binding and the presence of receptor antagonists . Antibody-based assays typically maintain better performance in these contexts.

• Technical simplicity: Standardized antibody-based assays like ELISAs are generally more straightforward to perform than bioassays .

• Clinical applicability: Antibody-based assays have proven more suitable for clinical specimens compared to bioassays .

How can IL-1R1 antibodies be utilized to investigate T-cell responses to viral antigens?

IL-1R1 antibodies serve as valuable tools for investigating T-cell responses to viral antigens through multiple experimental approaches:

Flow cytometry with IL-1R1 antibodies enables identification and quantification of IL-1R1 expression on antigen-specific CD4+ T cells. Research has demonstrated that SARS-CoV-2 spike protein-specific CD4+ T cells show upregulated IL-1R1 expression in both healthy subjects and patients with primary antibody deficiency (PAD) . This technique can be combined with intracellular cytokine staining to correlate IL-1R1 expression with functional responses such as IFN-γ production.

More sophisticated approaches include mass cytometry and multiplexed single-cell RNA sequencing, which allow comprehensive phenotyping of IL-1R1-expressing T cells in response to viral antigens . These techniques provide insights into the heterogeneity of antigen-specific T cell populations and the relationship between IL-1R1 expression and other functional markers.

Neutralizing IL-1R1 antibodies can be employed in both in vitro and in vivo experimental systems to assess the functional significance of IL-1R1 signaling. For example, research in mice demonstrated that neutralizing IL-1R1 during COVID-19 mRNA vaccination decreased IFN-γ expression by spike protein-specific CD4+ T cells and reduced the development of anti-spike protein IgG antibodies .

What is the role of IL-1R1 signaling in T-cell dependent antibody responses?

IL-1R1 signaling plays a critical role in T-cell dependent antibody responses through a well-defined mechanistic pathway:

The mechanism begins with IL-1R1 activation on T cells, which stimulates the NF-κB signaling pathway . This activation contributes to T cell activation and differentiation, particularly toward phenotypes that provide effective help to B cells . The quality of this T cell help directly influences B cell responses, including class switching, affinity maturation, and antibody production .

Research has demonstrated the significance of this pathway in multiple experimental systems. Following COVID-19 mRNA vaccination, the expression levels of IL-1R1 on spike protein-specific CD4+ T cells correlated with the development of serum anti-spike protein IgG antibodies in healthy individuals . This correlation provides compelling evidence for the importance of IL-1R1 signaling in vaccine-induced humoral immunity.

The Adverse Outcome Pathway (AOP) framework further supports this relationship, identifying "Impaired IL-1R1 signaling leading to Impaired T-Cell Dependent Antibody Response" as a recognized pathway with high evidence strength . This framework connects IL-1R1 signaling inhibition to NF-κB inhibition, suppression of T cell activation, and ultimately impairment of T-cell dependent antibody responses .

How can researchers develop IL-1R1 antibodies with improved species cross-reactivity?

Developing IL-1R1 antibodies with robust cross-species reactivity represents a significant challenge in translational research. For toxicological studies and preclinical development, antibodies must bind the ortholog antigen with similar affinity to the human target to enable relevant dosing regimens .

Advanced antibody engineering approaches can address the "species affinity gap" - the difference in binding affinity between human and animal orthologs of IL-1R1. One sophisticated approach involves mammalian recombination signal sequence (RSS)-directed recombination for complementarity-determining region (CDR)-targeted protein engineering combined with mammalian display technology . This methodology allows for:

• Generation of diversified antibody libraries through separate targeting of heavy chain and light chain sequences

• Screening of variants using multiple rounds of fluorescence-activated cell sorting (FACS)

• Selection of candidates with comparable affinity for human and animal orthologs

This non-hypothesis-driven affinity maturation method has generated antibodies with extraordinarily high affinity while addressing species cross-reactivity challenges . The approach allows researchers to develop antibodies that maintain consistent binding properties across species, facilitating more reliable translation of preclinical findings to human applications.

What are common challenges in IL-1R1 antibody-based detection and how can they be addressed?

Researchers commonly encounter several challenges when working with IL-1R1 antibodies:

• Variable expression levels: IL-1R1 expression can fluctuate significantly depending on cell activation status and tissue type. To address this challenge, include appropriate positive controls known to express IL-1R1, such as Jurkat cells, MOLT-4 cells, or mouse spleen tissue . Time-course experiments may be necessary to capture dynamic expression patterns.

• Antigen retrieval complications: For IHC applications, successful IL-1R1 detection depends on effective antigen retrieval. The recommended approach uses TE buffer at pH 9.0, though citrate buffer at pH 6.0 represents an alternative . Optimization of retrieval conditions may be necessary for specific tissue types.

• Detection of multiple forms: IL-1R1 appears at both 80 kDa and 60 kDa in Western blot applications . Ensure gel resolution and detection parameters can accommodate both forms, as their relative abundance may vary across experimental conditions and cell types.

• Non-specific binding: As with many cytokine receptor antibodies, background signal can present challenges. Optimize blocking conditions using appropriate blocking agents (BSA, serum, or commercial blockers) and carefully titrate antibody concentrations to maximize signal-to-noise ratios.

• Sample-dependent variability: The optimal antibody concentration often varies by sample type . Perform titration experiments with each new experimental system rather than relying solely on manufacturer recommendations.

• Species compatibility: Verify that your chosen antibody recognizes IL-1R1 in your experimental species. Some antibodies exhibit differential affinity across species, which can complicate cross-species studies .

How can researchers assess the functional impact of IL-1R1 antibodies on downstream signaling?

Assessing the functional impact of IL-1R1 antibodies requires experimental approaches that examine downstream signaling events and biological outcomes:

NF-κB activation represents a primary readout for IL-1R1 signaling . Researchers can employ NF-κB reporter assays, Western blotting for phosphorylated IκB or p65 translocation, or electrophoretic mobility shift assays to monitor this pathway. These approaches can determine whether an IL-1R1 antibody exerts neutralizing effects or triggers receptor signaling.

For T cell activation assessment, flow cytometric analysis of activation markers (CD25, CD69) and measurement of cytokine production (particularly IFN-γ) serve as valuable functional readouts . IL-1β has been shown to promote IFN-γ expression by antigen-stimulated CD4+ T cells, supporting the functional implication of IL-1R1 in T cell responses .

Given the role of IL-1R1 in T-cell dependent antibody responses, measuring antigen-specific antibody production provides a downstream biological outcome measure. Research has demonstrated that neutralizing IL-1R1 in mice immunized with COVID-19 mRNA vaccine reduced the development of anti-spike protein IgG antibodies .

Phosphoprotein analysis using phospho-specific antibodies to detect activation of immediate signaling molecules downstream of IL-1R1 (such as IRAK1/4 and TRAF6) offers additional mechanistic insights into antibody effects on receptor function.

How should IL-1R1 antibodies be incorporated into experimental designs studying vaccine responses?

Incorporating IL-1R1 antibodies into vaccine response studies requires thoughtful experimental design:

For basic characterization, flow cytometry with IL-1R1 antibodies enables quantification of IL-1R1 expression on antigen-specific T cells following vaccination. Research has demonstrated that after the second dose of COVID-19 mRNA vaccines, spike protein-specific CD4+ T cells with high levels of IL-1R1 increased, likely reflecting repetitive antigenic stimulation .

Correlation analyses can evaluate relationships between IL-1R1 expression on antigen-specific T cells and antibody development. Studies have shown that expression levels of IL-1R1 on spike protein-specific CD4+ T cells correlated with serum anti-spike protein IgG antibody development in healthy individuals following COVID-19 vaccination .

For mechanistic investigations, neutralizing IL-1R1 antibodies can be administered during vaccination in animal models. This approach has demonstrated that blocking IL-1R1 signaling during COVID-19 mRNA vaccination decreased both IFN-γ expression by antigen-specific CD4+ T cells and the development of antigen-specific antibodies .

Comparative studies across different vaccine platforms can assess whether the role of IL-1R1 signaling varies between vaccine types. Research suggests IL-1R1 signaling may be relevant to both mRNA-based and conventional vaccines .

How might IL-1R1 antibodies contribute to precision immunology and personalized medicine?

IL-1R1 antibodies have significant potential to advance precision immunology and personalized medicine through several emerging applications:

The identification of IL-1R1 expression patterns on antigen-specific T cells may serve as biomarkers for predicting vaccine responsiveness. Research has demonstrated correlations between IL-1R1 expression levels on spike protein-specific CD4+ T cells and the development of antibody responses following COVID-19 vaccination . This suggests that IL-1R1 expression patterns could potentially identify individuals likely to respond suboptimally to vaccination, allowing for personalized vaccination strategies.

In patients with immune disorders, IL-1R1 expression analysis may provide insights into underlying mechanisms. Studies in patients with primary antibody deficiency (PAD) have identified altered patterns of IL-1R1 expression on antigen-specific T cells compared to healthy individuals . Further characterization of these patterns could help stratify patients and guide targeted therapeutic approaches.

Therapeutic antibodies targeting IL-1R1 may offer precision approaches for modulating immune responses in various conditions. By selectively enhancing or inhibiting IL-1R1 signaling, these therapeutics could address specific immune dysfunctions while minimizing off-target effects.

Additionally, IL-1R1 antibodies may contribute to assessing immunotoxicological profiles of drugs and environmental chemicals. The established adverse outcome pathway linking impaired IL-1R1 signaling to impaired T-cell dependent antibody responses provides a framework for evaluating potential immunomodulatory effects .

What emerging technologies might enhance IL-1R1 antibody applications in research?

Several cutting-edge technologies are poised to expand the utility of IL-1R1 antibodies in immunological research:

Single-cell analysis technologies represent a significant advancement, allowing researchers to correlate IL-1R1 expression with comprehensive cellular phenotypes at unprecedented resolution. Multiplexed single-cell RNA sequencing combined with protein detection (CITE-seq) enables simultaneous measurement of IL-1R1 protein expression and whole-transcriptome profiling at the single-cell level . This approach has been employed to characterize antigen-specific T cells, revealing heterogeneity in IL-1R1 expression patterns and associated functional states.

Mass cytometry (CyTOF) further enhances multiparametric analysis by allowing simultaneous detection of dozens of proteins, including IL-1R1, on single cells without fluorescence spillover limitations . This technology enables detailed phenotyping of IL-1R1-expressing cells in complex immune responses.

Spatial transcriptomics and imaging mass cytometry represent emerging approaches that could incorporate IL-1R1 antibodies to visualize receptor expression in tissue contexts while preserving spatial relationships between cells. These technologies would provide insights into the microenvironmental factors influencing IL-1R1 expression and function.

Advances in antibody engineering, including bispecific antibodies and antibody-drug conjugates, could expand IL-1R1 targeting capabilities. For example, bispecific antibodies could simultaneously target IL-1R1 and another relevant molecule to modulate specific immune cell functions in complex diseases.

How might understanding IL-1R1 signaling inform novel vaccination strategies?

Insights into IL-1R1 signaling offer several promising avenues for enhancing vaccination strategies:

Research findings suggest that modulating IL-1 production and its receptor system could potentially enhance vaccine efficacy . This approach might be particularly valuable for improving responses in populations that typically exhibit suboptimal vaccine responses, such as the elderly or immunocompromised individuals.

Novel adjuvant development represents a practical application of IL-1R1 research. Adjuvants that selectively enhance IL-1 production or IL-1R1 signaling in antigen-presenting cells and T cells could potentially boost vaccine-induced immune responses. This approach would leverage the natural role of IL-1R1 signaling in promoting T cell activation and subsequent antibody development .

For mRNA vaccines specifically, understanding the role of IL-1R1 in response to these platforms could inform optimization strategies. Research has demonstrated that IL-1R1 expression increases on antigen-specific T cells following mRNA vaccination and correlates with antibody development . This suggests that ensuring proper IL-1R1 signaling could be critical for maximizing mRNA vaccine efficacy.

In vaccine development for special populations, such as patients with primary antibody deficiency, targeting the IL-1/IL-1R1 axis might offer personalized approaches. Studies have observed IL-1R1 upregulation on antigen-specific T cells in these patients following vaccination, though the correlation with antibody development differs from healthy individuals . This suggests that additional immune pathways may require modulation in these populations.